New drug combo shows promise for Tough-to-Treat lymphoma
NCT ID NCT03278782
First seen Jan 10, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This early-stage trial is testing whether combining two drugs—pembrolizumab (Keytruda) and romidepsin (Istodax)—can safely and effectively treat peripheral T-cell lymphoma that has returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while romidepsin blocks enzymes that cancer cells need to grow. The study involves 39 participants and aims to find the best dose and measure how well the combination works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MYCOSIS FUNGOIDES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda) and romidepsin (Istodax)
What this could lead to
If this combination works, it could offer a new treatment option for patients with peripheral T-cell lymphoma that has come back or not responded to prior therapy.
What could go wrong
This is an early-phase trial with only 39 participants, so results may not apply to all patients. The combination may cause significant side effects, and it is not yet known if it will be more effective than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.